Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T-DM1-related telangiectasias: a potential role in secondary bleeding events.
Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL, Dalenc F, Delord JP. Sibaud V, et al. Among authors: delord jp. Ann Oncol. 2015 Feb;26(2):436-7. doi: 10.1093/annonc/mdu533. Epub 2014 Nov 17. Ann Oncol. 2015. PMID: 25403586 Free article. No abstract available.
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Theodore C, Chevreau C, Yataqhene Y, Fizazi K, Delord JP, Lotz JP, Geoffrois L, Kerbrat P, Bui V, Flechon A. Theodore C, et al. Among authors: delord jp. Ann Oncol. 2008 Aug;19(8):1465-1469. doi: 10.1093/annonc/mdn122. Epub 2008 Apr 2. Ann Oncol. 2008. PMID: 18385203 Free article. Clinical Trial.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: delord jp. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B, Gomez-Roca C, Boulanger M, Sibaud V. Vigarios E, et al. Among authors: delord jp. Br J Dermatol. 2015 Jun;172(6):1680-1682. doi: 10.1111/bjd.13610. Epub 2015 Apr 19. Br J Dermatol. 2015. PMID: 25495246 No abstract available.
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P. Isambert N, et al. Among authors: delord jp. Ann Oncol. 2015 May;26(5):1005-1011. doi: 10.1093/annonc/mdv031. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646368 Free article. Clinical Trial.
241 results